DRUG STUDY 1

DRUG DRUG CLASS INDICATION ACTION CONTRAINDICATION DOSAGE NURSING IMPLICATIONS

AND
ROUTEQ
SIMVASTATIN Lipid-lowering Adjunct to dietary Inhibit the enzyme NS:Headache,asthenia  Assess nutrition:
Agent therapy in the 3-hydroxy- , fat, protein,
management of primary methylglutaryl sleep disturbances carbohydrates
hypercholesterolemia coenzyme A (HMG GI: Flatulence,
and mixed dyslipidemia. CoA) reductase, diarrhea, abdominal  Monitor bowel
which is pain, cramps, pattern daily
Reduction of responsible for constipation, nausea,
lipids/cholesterol. catalyzing an early dyspepsia, heartburn,  Monitor
Reduces the risk for MI step in the liver failure triglycerides,
and stroke sequelae. synthesis of the Respiratory: Sinusitis, cholesterol
cholesterol. pharyngitis baseline
Other: throughout
THERAPEUTIC Rhabdomyolysis, treatment
EFFECTS: acute renal failure,  Precautions:
Lowering total & arthralgia, myalgia Past liver disease,
LDL cholesterol alcoholism, severe acute
infections, trauma, severe
metabolic disorders,
electrolyte imbalances,
elderly, renal disease
DRUG STUDY 2

DRUG DRUG CLASS INDICATION ACTION CONTRAINDIC DOSAGE NURSING IMPLICATIONS

ATION AND
ROUTE
CITICOLINE Neuroprotec Treatment Pharmacology: Somazine contains as its Patients with 1 gm TIV  The cardiovascular
tive of cerebrovascul single active component, parasympathe q8h status of the patient
CNS Drugs & ar accident in cytidine-5-diphosphate choline. CDP- tic hypertonia should be carefully
Agents for acute and choline is a biologic product. It is found evaluatedbefore
ADHD recovery phase, in the body and takes part in the rapidly administering
symptoms and biosynthesis of phospholipids which mannitol since
signs of cerebral integrate into the structures of the sudden expansion of
insufficiency nervous system especially in the theextracellular fluid
eg,dizziness, me membranes of the neurons. The may lead to
mory loss, formation of phospholipids is needed for fulminating
poor the re-structuring of cell membranes by congestive heart
concentration, the damaged neurons. Citicoline is an failure.
disorientation, interneuronal communication enhancer.  Somazine must not
recent cranial It increases the neurotransmission levels be administered
trauma and their because it favors the synthesis and along with
sequelae production speed of dopamine in the medicaments
striatum, acting then as a dopaminergic containing
agonist thru the inhibition of tyrosine- meclophenoxate
hydroxylase. Citicoline acts as a
presynaptic cholinergic agent which
favors the synthesis of acetylcholine. It
also decreases the release of serotonin.
Citicoline improves neuronal
metabolism in those cases where there
is a neuronal deterioration due to
degenerative, toxic or ischemic cause.
The cause of poor neuronal metabolism
is brought about by a decrease in
neuronal activity which makes the
astrocytes swell.
Swelling is due to electrolyte imbalance.
Active neurons release potassium
ions. These are taken up by astrocytes
(K+ buffers) and distributed to regions
with less K+. When neuronal activity
decreases, less K+ is released,
astrocytes take up Na+ instead of K+.
The hydrated Na+ is larger than the
hydrated K+ and so the astrocyte swells.
Improvement of neurometabolism is
demonstrated by citicoline's ability of
restoring the activity of mitochondrial
ATPase and of membranal
Na+/K+ ATPase. Citicoline also increases
glucose incorporation aside from
metabolism while at the same time
decreasing blactate accumulation in the
brain. Citicoline makes the neurons
more active, causing the astrocytes to
loosen their grip on the capillaries, thus
improving microcirculation. By virtue of
this action, citicoline has an indirect
effect on microcirculation. It has the
ability to slightly increase cerebral blood
flow and exerts an anti-aggregation
effect on platelets.
DRUG STUDY 3
DRUG DRUG CLASS INDICATION ACTION CONTRAINDIC DOSAGE NURSING IMPLICATIONS
ATION AND
ROUTE
LACTULOSE Anti-Allergic Constipatio Inhibits bacterial DNA gyrase thus Patient who 30 cc  Assess condition
Anti- n, preventing replication in susceptible require a ODHS before therapy and
histamine salmonello bacteria low lactose oral reassess regularly
sis. diet. thereafter to monitor
Treatment Galactosemia drug’s effectiveness
of hepatic deficiency.  Monitor patient for
encephalo Intestinal any adverse GI
pathy obstruction. reactions, nausea,
vomiting, diarr
hea.
 Assess for adverse
reactions
for pt. with hepatic
encelopathy:
-regularly assess
mental condition
-monitor I & O
-monitor for Inc.
glucose level in
diabetic patients